Diabetes treatments now 8.4% of UK annual NHS drugs bill, says report

24 August 2011

Diabetes prescriptions now account for 8.4 per of the entire National Health Service net bill for primary care drugs in England, a new report from The NHS Information Centre shows today. The percentage increase in the total cost of prescriptions for the condition was four times that in prescription cost overall between 2005/6 and 2010/11 - taking the cost of diabetes prescribing to £725 million ($1.2 billion) in 2010/11.

Prescribing for Diabetes; England, 2005/06 – 2010/11, also shows that in the same period the number of diabetes prescription items increased by 41% to reach 38.3 million items – meaning that one in every 25 prescription items written is now for diabetes.

The report examines prescribing trends between 2005/06 and 2010/11 for medicines used in the treatment of diabetes, and shows that in primary care in England, in 2010/11:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >